检索结果-南通市图书馆

The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy

引用

Journal of Cancer Therapy 2022年第9期13卷 561-584页

作者： Karen López Miguel Daniel Ricardo Martínez Ávila Lliset Álvarez Pérez Gisselle Martínez Rabasa Alejandro Linchenat Lambert Roberto Esperón Noa Lisandra Heredia Manzano Margarita De Quesada Amigó Rafael I. Reyes Velázquez Danay Corrales Otero Ramon Ropero Toirac Idelmis Curbelo Heredia Mircea Betancourt Cabeza Tania A. Agrelo Ramos Rosa María Muñoz Reyes Juan Jesús Lence Anta Rosalía Fuentes Sosa Karelia Silvera Candó Kirenia Silva Rodríguez Zaida Lastre Sosa mayte robaina garcía Eduardo Sanz David Marquez Department of Medical Oncology INOR La Habana Cuba Department of Gynaeco-Oncology INOR La Habana Cuba Department of Anatomical Pathology INOR La Habana Cuba Department of Imaging INOR La Habana Cuba Clinical Research Section INOR La Habana Cuba Department of Onco-Psychology INOR La Habana Cuba Clinical Laboratory Department INOR La Habana Cuba Clinical Trials Pharmacy Department INOR La Habana Cuba Department of Biostatistics CENCEC La Habana Cuba Scientific Department CATALYSIS Madrid Spain

Background: 70% of ovarian cancer cases are diagnosed at an advanced stage (III or IV) of the disease and, in turn, with a high prevalence of peritoneal carcinosis and ascites, which leads to progressive malnutrition in patients, with the consequent deterioration of their general condition. There is a very important relationship between nutritional status, quality of life, survival, and the ability to tolerate multidisciplinary treatment of peritoneal carcinosis. Methods: A phase II, open-label, single-center, non-randomised clinical trial was conducted that included 36 patients with advanced disease who were administered the nutritional supplement Ocoxin, 30 ml twice a day, beginning one week before chemotherapy (CT) based on carboplatin/paclitaxel, of which they receive three cycles with neoadjuvant intent. Ocoxin treatment was continued during chemotherapy and for three weeks after completion of the last cycle, as well as during any periods for which this treatment was discontinued due to toxicity. The effect of Ocoxin on the quality of life was assessed through the QLQ C30 and QLQ OV28 questionnaires from the start of treatment until the end of the follow-up period. In addition, the Karnofsky Index and nutritional parameters were assessed. Results: There were no significant differences between adverse events versus baseline values, except in leukocytes, lymphocytes, neutrophils, ALT, and AST. There was no deterioration of the QoL scales, except for those related to the effects of chemotherapy and alopecia. Conclusions: Ocoxin as an adjuvant to chemotherapy appears to improve better tolerance to chemotherapy, showed a good safety profile, and improved quality of life. For further information on Ocoxin neoadjuvant therapy benefits, a phase III clinical trial will be needed.

关键词： Chemotherapy Radiotherapy Ovarian Cancer Oncology Quality of Life Ad-juvant Therapy Supportive Care

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer

引用

World Journal of Clinical Oncology 2022年第4期13卷 237-266页

作者： Nuria Rodriguez De Dios Arturo Navarro-Martin Cristina Cigarral Rodolfo Chicas-Sett Rafael garcia Virginia garcia Jose Antonio Gonzalez Susana Gonzalo Mauricio Murcia-Mejia Rogelio robaina Amalia Sotoca Carmen Vallejo German Valtuena Felipe Counago Department of Radiation Oncology Hospital del MarBarcelona 08003Spain Radiation Oncology Research Group Hospital Del Mar Medical Research InstitutionBarcelona 08003Spain Department of Experimental and Health Sciences Pompeu Fabra UniversityBarcelona 08003Spain Department of Radiation Oncology Thoracic Malignancies UnitHospital Duran i Reynals.ICOL´Hospitalet de LLobregat 08908Spain Department of Radiation Oncology Hospital Clinico de SalamancaSalamanca 37007Spain Department of Radiation Oncology ASCIRES Grupo BiomedicoValencia 46004Spain Department of Radiation Oncology Hospital Ruber InternacionalMadrid 28034Spain Department of Radiation Oncology Hospital Universitario Arnau de VilanovaLleida 25198Spain Department of Radiation Oncology Genesis Care-SpainSevilla 41092Spain Department of Radiation Oncology Hospital Universitario La PrincesaMadrid 28006Spain Department of Radiation Oncology Hospital Universitario Sant Joan de ReusReus 43204TarragonaSpain Department of Radiation Oncology Hospital Universitario Ramon y CajalMadrid 28034Spain Department of Radiation Oncology Hospital Clinico Universitario Lozano BlesaZaragoza 50009Spain Department of Radiation Oncology Hospital Universitario QuirónsaludMadrid 28223Spain Department of Radiation Oncology Hospital La LuzMadrid 28003Spain Department of Clinical Universidad EuropeaMadrid 28670Spain

Non-small cell lung cancer(NSCLC) is a heterogeneous disease accounting for approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early stage. Treatment is multidisciplinary and radiotherapy plays a key role in all stages of the disease. More than 50% of patients with NSCLC are treated with radiotherapy(curative-intent or palliative). Technological advancesincluding highly conformal radiotherapy techniques, new immobilization and respiratory control systems, and precision image verification systems-allow clinicians to individualize treatment to maximize tumor control while minimizing treatment-related toxicity. Novel therapeutic regimens such as moderate hypofractionation and advanced techniques such as stereotactic body radiotherapy(SBRT) have reduced the number of radiotherapy sessions. The integration of SBRT into routine clinical practice has radically altered treatment of early-stage disease. SBRT also plays an increasingly important role in oligometastatic disease. The aim of the present guidelines is to review the role of radiotherapy in the treatment of localized, locally-advanced, and metastatic NSCLC. We review the main radiotherapy techniques and clarify the role of radiotherapy in routine clinical practice. These guidelines are based on the best available evidence. The level and grade of evidence supporting each recommendation is provided.

关键词： Radiotherapy Non-small cell lung cancer Guidelines Stereotactic radiation therapy Hypofractionated radiation Oligometastasis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Spontaneous Mammary Carcinomas in Female Dogs:Association between the Immunohistochemical Degree of Aggressiveness of Tumors,Intensity of DNA Damage and Residues of Pyrethroids

引用

Open Journal of Pathology 2013年第3期3卷 133-137页

作者： Yara de Oliveira Brandao Marcia Moleta Colodel Glenda Nicioli da Silva Stephane Cássia Vexenat Isabelle Ferreira Yame Fabres robaina Sancler da Silva Camilo Bulla Noeme Sousa Rocha Department of Clinical Veterinary Medicine Laboratory of Investigative and Comparative PathologySchool of Veterinary Medicine and Animal ScienceSao Paulo State UniversityBotucatuBrazil Departament of Pathology School of MedicineSao Paulo State UniversityBotucatuBrazil Laboratory of Biomedical Vibrational Spectroscopy(LEVB) Institute of Research and DevelopmentUniversidade do Vale do ParaíbaUrbanovaBrazil Department of Reproduction Sao Paulo State UniversityBotucatuBrazil Department of Pathobiology and Population Medicine College of Veterinary MedicineMississippi State UniversityStarkvilleUSA

Diagnosis and biological behavior of breast cancer of female dog represent one of the biggest challenges facing the Veterinarian in recent years. Due to its exponential growth and the degree of aggressiveness, the exact cause of this tumor is probably multifactorial and it is believed that may suffer influence from environmental factors. Among the suspected environmental contaminants are the pyrethroids. Aiming to investigate the participation of pyrethroids in tumorigenesis in female dogs, a study was conducted using 50 female dogs, 22 were positive for simple breast carcinoma (Group I), 18 with a diagnosis of complex breast carcinoma (Group II) and 10 negative (Group III) for breast cancer. In order to detect DNA damage, the Comet assay was performed on mammary samples of these animals, which also had samples submitted to the technique of High Performance Liquid Chromatography (HPLC), which aimed to quantify the concentration of pyrethroids. The results of HPLC of each animal were compared with those obtained by the Comet assay analysis of variance and the means were compared by the test groups “Student T” at the significance level of p ￡ 0.05. Despite presenting correlation between the amount of DNA damage and tumor aggressiveness, no statistical differences were found in the DNA damage of different histologic types of breast carcinoma. As for pyrethroids, even these were detected in 22% of tumor tissues and peritumoral fat, there was no difference in DNA damage between cells exposed and not exposed to environmental contaminant.

关键词： Mammary Carcinomas DNA Damage Pyrethroids

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：